Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- Will Japan Reinstate Sakigake Status for Aducanumab? Many See It Unlikely
November 15, 2019
- Only 2.4% of Pharmacies Have Generic Drug Formularies in Their Region: Tokyo Govt Survey
November 15, 2019
- PMD Law Amendment Bill Clears Lower House Health Panel
November 14, 2019
- Forteo, Enbrel Biosimilars OK’ed for Self-Injection; Evrenzo under Flat-Fee System
November 14, 2019
- Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
November 14, 2019
- Panel OKs Orphan Status for 3 Cell, Gene Therapies
November 14, 2019
- Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
November 13, 2019
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor Up for MHLW Panel Review on Nov. 25; 2 More Indications for Keytruda Also on Agenda
November 12, 2019
- Public-Private Confab Set for November 18; 2020 Reform, PMD Law Up for Discussion
November 12, 2019
- MHLW Sees No Major Problem with Current Rules for Low-Price Products, Chuikyo Questions Price Negotiation Process
November 12, 2019
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- PMDA Reviewing Safety Risks for Tecentriq, Tagrisso and More
November 12, 2019
- Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
- Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
- LDP Lawmakers to Launch Group to Reinstate HPV Vaccine Recommendation
November 11, 2019
- Opposition Party Set to Compile HPV Vaccine Proposal by Year-End
November 8, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Zolgensma Not on Roster for Nov. 13 MHLW Panel Review
November 7, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…